MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

Julian Panés  ¹     Bram Verstockt  ²     Valerie Pivorunas  ³     James Butler  ⁴     Naim Mahi  ⁴     Melanie Ruzek  ⁴     Thierry Sornasse  ⁵     James Fann  ⁵     Feng Hong  ⁵     Xiaohong Cao  ⁶     Nizar Smaoui  ⁶     Justin Wade Davis  ⁶     Jasmina Kalabic  ⁷     Alexandra Song  ⁷     Azucena Salas  ⁷     Tariq Ahmad  ⁸     Severine Vermeire  ⁸     Heath M. Guay  ⁸     Nick Kennedy  ^8    
1 Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
² University Hospitals Leuven, Catholic University of Leuven, Leuven, Belgium
³ AbbVie Bioresearch Center, Worcester, United States
⁴ AbbVie Inc., North Chicago, United States
⁵ AbbVie Redwood City, Redwood City, United States
⁶ AbbVie Cambridge Research Center, Cambridge, United States
⁷ AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
⁸ Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

Topic
IBD, Immunology

Session
IBD: Clinical trials IV

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)